T-Cypher Bio is an early-stage, innovative biotechnology company based in Oxford, UK.
We believe that TCR-based therapeutics have the potential to transform the treatment of solid tumours, as well as autoimmune, inflammatory, and infectious diseases. Yet challenges in the identification of therapeutically relevant targets and TCRs has limited the application of such therapies.
T-Cypher’s integrated platform, D-Cypher, overcomes these challenges.
Location: United States, Ohio, Oxford
Employees: 11-50
Founded date: 2021
Investors 3
Mentions in press and media 2
| Date | Title | Description | Source |
| 29.07.2021 | T-Cypher Bio Announces Formation of Scientific Advisory Boar... | PRESS RELEASE T-Cypher Bio Announces Formation of Scientific Advisory Board Oxford, UK, 29 July 20... | marketscre... |
| 15.07.2021 | T-Cypher Bio announces the appointment of Thomas Lars Andres... | PRESS RELEASE T-Cypher Bio announces the appointment of Thomas Lars Andresen as Chief Executive Off... | marketscre... |